恒瑞医药涨超3% Myosin抑制剂HRS-1893实现海外授权 交易额超10亿美元

Core Viewpoint - Heng Rui Medicine (600276) has entered into an exclusive licensing agreement with BraveheartBio for its self-developed Myosin small molecule inhibitor HRS-1893, which has led to a stock price increase of over 3.5% [1] Group 1: Licensing Agreement Details - The licensing agreement allows Heng Rui Medicine to develop, produce, and commercialize HRS-1893 globally, excluding mainland China, Hong Kong, Macau, and Taiwan [1] - BraveheartBio will pay Heng Rui Medicine a total of $75 million, which includes a $65 million upfront payment (comprising $32.5 million in cash and $32.5 million in BraveheartBio equity) and a $10 million milestone payment upon completion of technology transfer [1] - Heng Rui Medicine is also eligible to receive up to $1.013 billion in milestone payments related to clinical development and sales, along with corresponding sales royalties [1] Group 2: Financial Impact - Heng Rui Medicine's total amount from three business development (BD) transactions this year has exceeded $15 billion [1] - The stock price of Heng Rui Medicine rose to HKD 84.2, with a trading volume of HKD 155 million at the time of reporting [1]